- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 217/26 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Patent holdings for IPC class C07D 217/26
Total number of patents in this class: 394
10-year publication summary
|
28
|
27
|
19
|
30
|
25
|
22
|
20
|
28
|
20
|
10
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| FibroGen, Inc. | 144 |
22 |
| Bristol-myers Squibb Company | 4880 |
20 |
| Bayer Pharma AG | 1053 |
8 |
| Astellas Pharma Inc. | 1087 |
7 |
| City of Hope | 994 |
6 |
| BASF SE | 20940 |
5 |
| Abbvie Inc. | 1800 |
5 |
| Takeda Pharmaceutical Company Limited | 2708 |
5 |
| Bausch + Lomb Ireland Limited | 695 |
5 |
| Novartis AG | 10744 |
4 |
| Bayer AG | 3325 |
4 |
| Cytokinetics, Inc. | 279 |
4 |
| Dr. Reddy's Laboratories Limited | 555 |
4 |
| Lupin Limited | 432 |
4 |
| Tongli Biomedical Co., Ltd | 31 |
4 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2855 |
4 |
| H. Lundbeck A/S | 1250 |
4 |
| Cytosinlab Therapeutics Co., Ltd. | 15 |
4 |
| F. Hoffmann-La Roche AG | 7947 |
3 |
| Sandoz AG | 1417 |
3 |
| Other owners | 269 |